Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of News

<< 2011 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2013 >>

19 April 2012: UCL and ARUP Renew Partnership

UCL and Arup have reviewed and renewed their established partnership. By doing so, the global consultancy firm hopes to boost its collaboration and training activities with the university in fields which range from sustainable development through engineering to behavioural sciences.
More...

<< 2011 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2013 >>